Cleveland, November 4, 2025 — Sotera Health Company (Nasdaq: SHC) reported a 9.1% increase in Q3 2025 net revenues to $311 million, or 8.0% on a constant currency basis, compared to Q3 2024. Net income reached $48 million, or $0.17 per diluted share, up from $17 million, or $0.06 per diluted share, in Q3 2024. Adjusted EBITDA increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024. Adjusted EPS rose to $0.26, an increase of $0.09 per diluted share, compared to $0.17 in Q3 2024. The company is raising its 2025 Adjusted EBITDA growth range to 6.75% – 7.75% and reaffirming its net revenues outlook range of 4.5% – 6.0% on a constant currency basis.
For the first nine months of 2025, Sotera Health’s net revenues grew by 6.2% to $860 million compared to $810 million in the same period of 2024. Net income stood at $43 million, or $0.15 per diluted share, inclusive of settlements related to ethylene oxide claims. Adjusted EBITDA for the same period increased by 10.4% to $437 million.
Sotera Health is updating its 2025 outlook, projecting net revenues growth between 4.5% and 6.0% on a constant currency basis, with foreign currency exchange contributing approximately 25 basis points. The Adjusted EBITDA growth range is raised to 6.75% to 7.75%, with a similar contribution from foreign currency. The interest expense range is improved to $154 million to $158 million, and the Adjusted EPS range is raised to $0.81 to $0.86.
Updates on recent developments in matters relevant to investors can be found on the Investor Relations section of the Sotera Health website at Investor Relations | Sotera Health. For developments related to EO, updates can be found at Ethylene Oxide | Sotera Health.
INVESTOR RELATIONS CONTACTS
Jason Peterson
Vice President Investor Relations, Sotera Health
IR@soterahealth.com
MEDIA
Kristin Gibbs
Chief Marketing Officer, Sotera Health
kgibbs@soterahealth.com
Source: Sotera Health Company
